Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

We have observed 34 EP applications Lindsey Ruth Kent has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after August 17, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12719889

c-KIT ANTIBODIES AND USES THEREOF

IPC classification:
A61K 45/06, A61K 39/395, C07K 16/28
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP12761863

ANTIBODIES TO PCSK9 AND USES THEREOF

IPC classification:
C07K 16/40
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP12833842

ANTI-C-MET ANTIBODIES

IPC classification:
A61K 39/395, C12P 21/08, C07K 16/00
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
APPLICATION WITHDRAWN
EP14181801

Anti-myostatin antibodies

IPC classification:
A61K 39/395, C07K 16/22, A61P 21/00, A61P 3/00
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
The patent has been granted
EP13710214

IL-17 ANTIBODY FORMULATION

IPC classification:
A61K 39/395, C07K 16/24
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP14190162

Pegylated amyloid beta fab

IPC classification:
A61K 47/48, A61K 39/395, C12N 15/13, C07K 16/18, A61P 25/28
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP13724063

TREATMENT FOR COMORBID DIABETES WITH CHRONIC KIDNEY DISEASE

IPC classification:
A61K 47/48, A61P 3/10
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP13787192

ANTI-C-MET ANTIBODIES

IPC classification:
C07K 16/28
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
The patent has been granted
EP15159780

DKK-1 ANTIBODIES

IPC classification:
A61K 39/00, C07K 16/18
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP13178615

Anti-sclerostin antibodies

IPC classification:
C07K 16/22, A61P 19/08, A61P 19/10, A61K 39/395
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP15175051

C-MET ANTIBODIES

IPC classification:
A61P 35/00, A61K 39/395, C07K 16/28
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14711895

ANTI-TNF-ANTI-IL-17 BISPECIFIC ANTIBODIES

IPC classification:
A61P 19/02, A61P 17/06, A61K 39/395, C07K 16/24
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP14711899

PAN-ELR+ CXC CHEMOKINE ANTIBODIES

IPC classification:
C07K 16/24, C07K 16/18
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP15196358

ANTI-N3PGLU AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

IPC classification:
A61P 25/28, A61K 39/395, G01N 33/577, C07K 16/18
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
The patent has been granted
EP14821418

NOVEL COMPOUND FOR TREATMENT OF SEVERE HYPOGLYCEMIA

IPC classification:
C07K 14/605
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
APPLICATION WITHDRAWN
EP14821985

NOVEL COMPOUND FOR TREATMENT OF SEVERE HYPOGLYCEMIA

IPC classification:
C07K 14/605
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14821986

NOVEL COMPOUND FOR TREATMENT OF SEVERE HYPOGLYCEMIA

IPC classification:
A61K 38/00, C07K 14/605
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14830758

MULTIFUNCTIONAL ANTIBODIES BINDING TO EGFR AND MET

IPC classification:
A61P 35/00, A61K 39/395, C07K 16/46, C07K 16/30, C07K 16/28
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15764397

IL-21 ANTIBODIES

IPC classification:
C07K 16/24
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15723388

RAPID-ACTING INSULIN COMPOSITIONS

IPC classification:
A61K 31/5585, A61K 38/28, A61P 3/10
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP16195503

IL-17 ANTIBODY FORMULATION

IPC classification:
C07K 16/24, A61K 39/395
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
Examination is in progress
EP15734541

THERAPY FOR GIST

IPC classification:
A61K 39/00, A61P 35/00, C07K 16/28
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15734537

COMBINATION THERAPY

IPC classification:
A61P 35/00, C07K 16/30, C07K 16/28, A61K 31/704, A61K 39/395
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15817678

RAPID-ACTING INSULIN COMPOSITIONS

IPC classification:
A61P 3/10, A61K 47/12, A61K 38/28
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16703620

GIP AND GLP-1 CO-AGONIST COMPOUNDS

IPC classification:
A61K 38/26, C07K 14/605, C07K 14/575
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16710352

NASAL POWDER FORMULATION FOR TREATMENT OF HYPOGLYCEMIA

IPC classification:
A61P 3/00, A61K 38/26, A61K 9/14
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16706741

ANTIBODIES TO TAU AND USES THEREOF

IPC classification:
C07K 16/18, A61K 39/00, A61P 25/28
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16713273

ANTI-CD20- / ANTI-BAFF BISPECIFIC ANTIBODIES

IPC classification:
A61K 39/00, A61P 37/00, C07K 16/46, C07K 16/28
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16721605

FUSION PROTEINS

IPC classification:
C12N 15/62, A61K 38/28, C07K 14/62
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16736267

ANTI-DKK-1-ANTI-RANKL BISPECIFIC ANTIBODY COMPOUNDS

IPC classification:
A61P 19/08, A61K 39/395, C07K 16/28, C07K 16/18
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
Request for examination was made
EP16741214

TREATMENT OF PRURITUS

IPC classification:
A61K 39/00, C07K 16/24
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
Request for examination was made
EP18150424

ANTI-N3PGLU AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

IPC classification:
A61P 25/28, A61K 39/395, G01N 33/577, C07K 16/18
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
The application has been published
EP16771021

RAPID-ACTING INSULIN COMPOSITIONS

IPC classification:
A61K 31/557, A61K 47/12, A61K 47/02, A61K 38/28, A61K 9/00
Applicant:
Eli Lilly and Company Limited
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
Request for examination was made
EP18153438

PAN ELR+ CXC CHEMOKINE ANTIBODIES

IPC classification:
C07K 16/24, C07K 16/18
Agent:
Lindsey Ruth Kent, Eli Lilly and Company Limited
Status:
The application has been published

Please Sign in to use this feature